Table 1 Demographic and clinical characteristics of enrolled SLE patients and subgroups based on the presence of organ damage and LN
Demographic and clinical features | SLE (n = 75) | Organ damage (n = 42) | No organ damage (n = 33) | LN (n = 27) | No LN (n = 48) |
|---|---|---|---|---|---|
Female/Male | 66/9 | 34/8 | 32/1 | 22/5 | 44/4 |
Age (years) mean (min–max) | 40 (19–74) | 44 (20–67) | 35 (19–74) | 35 (19–57) | 46 (25–64) |
Age at the onset of the disease (years) mean (min–max) | 27 (11–58) | 31 (11–58) | 26 (12–56) | 24 (12–55) | 33 (11–58) |
Duration of the disease (years) mean (min–max) | 11 (1–38) | 13 (1–38) | 10 (1–31) | 11 (1–20) | 13 (1–38) |
Organ damage (SDI ≥ 2/SDI = 1/SDI = 0)* | 25/17/33 | 25/17/0 | 0/0/33 | 10/5/12 | 15/12/21 |
Organ damage: SDI mean (min–max) | 1.2 (0–8) | 2.2 (1–8) | 0 (0–0) | 1.1 (0–5) | 1.3 (0–8) |
Lupus nephritis, biopsy proven (Y/N) | 27/48 | 15/27 | 12/21 | 27/0 | 0/48 |
Neurological involvement (Y/N)@ | 22/53 | 15/27 | 7/26 | 9/18 | 13/35 |
Hematological involvement (Y/N)# | 19/56 | 15/27 | 4/29 | 5/22 | 14/34 |
Cardiovascular involvement (Y/N)§ | 12/63 | 11/31 | 1/32 | 4/23 | 8/40 |
Skin and musculoskeletal involvement (Y/N)†| 56/19 | 28/14 | 28/5 | 6/21 | 35/13 |
Antiphospholipid syndrome (Y/N)$ | 23/52 | 15/27 | 8/25 | 6/21 | 17/31 |
Renal disorder (Y/N)# | 35/40 | 19/23 | 12/21 | 27/0 | 9/39 |
Disease activity: SLEDAI mean (min–max) | 7 (0–43) | 8.8 (0–43) | 4.7 (0–26) | 10.3 (0–43) | 5.2 (0–20) |
Active/inactive renal disease& | 17/58 | 12/30 | 5/28 | 13/14 | 4/44 |
Mean of cumulative dose of glucocorticoids (g) (min–max) | 22.8 (0–79.2) | 30.6 (2.6–79.2) | 12.8 (0–54.0) | 27.2 (2.4–68.4) | 20.3 (0–79.2) |